Discover Novel Inhibitors with the Transcreener AMP2 NUDT5 Assay
The Transcreener AMP² NUDT5 Assay directly measures the AMP produced by NUDT5 (also known as nudix hydrolase 5 or NUDIX5). By measuring the production of AMP researchers can effectively determine the activity of the NUDT5 enzyme. The assay provides a powerful tool to screen entire compound libraries for NUDT5 modulators to help find new therapeutics for diseases such as cancer.
The kit comes complete with all the detection reagents required to measure activity. NUDT5 enzyme and ADPR are not included in the inhibitor screening assay kit. Please contact us for questions related to acquiring the enzyme.
NUDT5 as a Drug Target
NUDIX hydrolases are a superfamily of enzymes that hydrolyze modified nucleoside diphosphates. NUDT1 (also known as MTH1) is one of the most well-studied NUDIX hydrolases, having been linked to a variety of disorders including Parkinson's disease and cancer. However, NUDT5 has lately attracted interest due to its link to some human malignancies. NUDT5 hydrolyzes 8-OH-dGDP, 8-OH-dADP, and ADP-ribose (ADPR) as well as other substrates.
High amounts of NUDT1 and NUDT5 have been found in non-small-cell lung cancer (NSCLC) cell lines and tissues, and greater levels of both proteins in NSCLC patients were linked to tumor metastasis. NUDT5 expression has been shown to be elevated in human breast cancer cell lines and breast tumor tissues. Patients with high NUDT5 expression profiles also exhibit significantly poorer prognoses than those with lower NUDT5 levels.